BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Degron Therapeutics Launches into Sizzling Hot Protein Degradation Space

  Degron Therapeutics, based in Shanghai, announced Thursday that it has secured $22 million in Series A financing for its unique molecular glue-based targeted protein degradation platform GlueXplorer.

  June 9, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Policy

  Game Day for bluebird bio: FDA to Assess First Lentiviral Vectors

  Bluebird bio faces a two-day crucible as the U.S. Food and Drug Administration’s Cell, Tissue and Gene Therapies Advisory Committee will give two lentiviral vector gene therapies a thumbs up or down.

  June 9, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Preclinical Study Backs Seelos’ Gene Therapy for Dementia with Lewy Bodies

  Seelos Therapeutics announced in vitro data Thursday supporting its gene therapy, SLS-004. SLS-004 is intended for the treatment of dementia with Lewy bodies (DLB).

  June 9, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  AbbVie, Biohaven, Teva and Satsuma Tackle Migraine at AHS

  The annual meeting of the American Headache Society (AHS) is being held in Denver, Colorado from June 9-12. Here’s a look at just some of the wide-ranging research being presented.

  June 9, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  BioSpace Movers & Shakers: Third Harmonic, Inozyme, Athira, Aurion and More

  Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.

  June 9, 2022

   · 

  7 min read

   · 

  Alex Keown
• 

  Changing the Narrative: Four Companies Working to Make Insulin More Accessible

  For the 37.3 million Americans who have diabetes, insulin has become increasingly expensive. Here are four organizations dedicated to making insulin more accessible.

  June 9, 2022

   · 

  6 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  All Aboard! Takeda’s Dengue Fever Vaccine Holds Up Over 4.5 Years

  Takeda announced results from its Phase III clinical trial on TAK-003, its dengue fever vaccine candidate, at the Northern European Conference of Travel Medicine.

  June 9, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Business

  Forbion Closes $500M Growth Fund to Boost Late-Stage European Companies

  The Forbion Growth Opportunities Fund II will invest mainly in later-stage biopharmaceutical firms in Europe, focusing on marketing treatments for diseases with high unmet needs.

  June 9, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  Novavax Delayed Again, Moderna’s Bivalent Vaccine and More Breakthrough Cases

  The FDA plans to review changes to Novavax’s manufacturing process before it authorizes its vaccine.

  June 9, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Tessa, Synklino, Anagenex and Charm Hit Series A Jackpot

  Tessa Therapeutics, Synklino, Anagenex and Charm Therapeutics raise tens of millions of dollars in Series A financing.

  June 9, 2022

   · 

  4 min read

   · 

  Alex Keown